Sort by
Refine Your Search
-
You are dedicated scientist with a background in chromatin biology and/or gene regulation and experience in cell engineering, molecular cloning, genomics, and computational data analysis workflows. In
-
Assessment Sciences (IRAS) as a PhD candidate in Exposomics, Machine Learning and AI! Your job In this PhD project, you will design and apply innovative computational approaches, such as graphical models
-
research programme in immunopharmacology. You are committed to further strengthening our existing expertise in immune-targeted therapies, inflammation biology, mucosal immunology, and immune modulation
-
at the local level or as part of the national master programme, Mastermath. You will be involved in the supervision of Bachelor's and Master's theses as well as smaller-scale projects. We value and encourage
-
of sediments, carbon, pollutants, nutrients, oxygen, and heat from the continental shelves to the deep ocean. Training A personalised training programme will be set up reflecting your training needs and career
-
. The project is embedded in the broader EMBRACER programme, which aims to advance our understanding of climate feedbacks. You will therefore collaborate with colleagues in climate science, systems modelling, and
-
and altered crystalline rocks presenting unique intermediate cases. Recent advances in operando micro-computed tomography (µCT) enable unprecedented real-time visualisation of these processes, yet
-
may be subjected to specific approval by the Board for Conferral of Doctoral Degrees, before the candidate can be accepted to the PhD programme. The project will require: Experience or strong interest
-
on preliminary results and research interests of the candidate. Training A personalised training programme will be set up reflecting your training needs and career objectives. About 20% of your time will be
-
Immunology programme and will be working in a supporting team environment were there is room for you personal development. PhD position 1 So far, the development of novel immunotherapies, such as vaccines and